# Swanbio Therapeutics (Swanbio Therapeutics Limited)

Private limited company registered in Stevenage, classed under “Research and experimental development on biotechnology”.

- Company number: 10942620
- Status: Active
- Type: Private limited company
- Incorporated: 1 September 2017
- Registered office: Sycamore House, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2BP
- Location: Stevenage, Hertfordshire
- Activity: Research and experimental development on biotechnology

## Latest filed profit

No profit figure in its latest filed accounts.

Turnover, net assets, cash, staff, earlier years, ratios and owners are on the page for subscribers.

## Questions people ask

### What does Swanbio Therapeutics do?

Private limited company registered in Stevenage, classed under “Research and experimental development on biotechnology”.

### How much turnover does Swanbio Therapeutics make?

Answered on the page for FirmFacts Pro subscribers: https://firmfacts.co/company/swanbio-therapeutics-10942620

### Is Swanbio Therapeutics profitable?

Swanbio Therapeutics's profit isn't public: small companies may file without a profit and loss account.

### How many people work at Swanbio Therapeutics?

Answered on the page for FirmFacts Pro subscribers: https://firmfacts.co/company/swanbio-therapeutics-10942620

### Who runs and owns Swanbio Therapeutics?

Its directors are Pope "Chip" McCorkle Iv, James Albert Bircher III, Paul Matthew Schneider. Its owners are shown to subscribers.

### Where is Swanbio Therapeutics based?

Its registered office is Sycamore House, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2BP, in Stevenage, Hertfordshire.

### When was Swanbio Therapeutics founded?

Swanbio Therapeutics Limited was incorporated on 1 September 2017.

### Is Swanbio Therapeutics still trading?

The register lists Swanbio Therapeutics Limited as active.

## Timeline

Recent filings and changes at Companies House.

- 2026-10-26: Audit exemption subsidiary accounts made up to 31 December 2025
- 2026-10-26: Consolidated accounts of parent company for subsidiary company period ending 31/12/25
- 2026-10-26: Notice of agreement to exemption from audit of accounts for period ending 31/12/25
- 2026-10-26: Audit exemption statement of guarantee by parent company for period ending 31/12/25 (and 2 more like it since 10 October 2025)
- 2026-08-18: Termination of appointment of Michael John Parini as a director on 31 July 2026
- 2025-12-23: Statement of capital on 23 December 2025 · GBP 0.00001
- 2025-12-23: Solvency Statement dated 23/12/25
- 2025-12-23: Resolutions (and 5 more like it since 21 February 2018)
- 2025-10-20: Total exemption full accounts made up to 31 December 2024
- 2025-10-10: Consolidated accounts of parent company for subsidiary company period ending 31/12/24
- 2025-10-10: Notice of agreement to exemption from audit of accounts for period ending 31/12/24
- 2024-11-04: Second filing of a statement of capital following an allotment of shares on 12 August 2024 · GBP 1,471.24281 (and 1 more like it since 2 June 2020)
- 2024-10-10: Cessation of Syncona Limited as a person with significant control on 19 March 2024
- 2024-10-10: Notification of Spur Therapeutics Holdings Limited as a person with significant control on 19 March 2024
- 2024-08-30: Statement of capital following an allotment of shares on 12 August 2024 · GBP 890.461397 (and 10 more like it since 13 May 2019)
- 2024-08-24: Memorandum and Articles of Association (and 3 more like it since 13 August 2019)
- 2024-08-24: Change of share class name or designation
- 2024-08-22: Appointment of Pope "Chip" Mccorkle Iv as a secretary on 12 August 2024
- 2024-08-22: Current accounting period extended from 30 September 2024 to 31 December 2024
- 2024-08-21: Registered office address changed from 8 Bloomsbury Street 2nd Floor London WC1B 3SR England to Sycamore House Gunnels Wood Road Stevenage Hertfordshire SG1 2BP on 21 August 2024
- 2024-07-09: Total exemption full accounts made up to 30 September 2023
- 2024-03-27: Director's details changed for Mr James Iii Albert Bircher on 14 March 2024
- 2024-03-27: Termination of appointment of John Tsai as a director on 14 March 2024
- 2024-03-27: Termination of appointment of Alison Lawton as a director on 14 March 2024
- 2024-03-27: Termination of appointment of Alexander Brian Hamilton as a director on 14 March 2024

---

Source: Companies House filings (Open Government Licence v3.0). Figures are as filed; nothing is estimated. Page: https://firmfacts.co/company/swanbio-therapeutics-10942620